DERM · Journey Medical Corp
$6.72
+0.07 (+1.05%)
At close · Aug 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, as a result of recurring and historical losses, substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$189.67M
Shares
28.22M
Journey Medical Corp Earnings Call Transcripts
Every quarterly earnings call for Journey Medical Corp (DERM) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲19.6%
$18.29M
−$7.53M
'22 Q2
22-08-09
▼17.8%
$16.12M
−$10.08M
'22 Q3
22-11-10
▼8.9%
$15.97M
−$10.64M
'22 Q4
23-03-29
▼47.6%
$12.21M
−$10.14M
'23 Q1
23-05-22
▼6.1%
$17.17M
−$8.36M
'23 Q2
23-08-08
▲114.3%
$34.54M
$16.79M
'23 Q3
23-11-07
▼4.4%
$15.26M
−$2.14M
'23 Q4
24-03-21
▲6.7%
$13.03M
−$10.44M
'24 Q1
24-05-13
▼13.5%
$14.86M
−$3.36M
'24 Q2
24-08-12
▼10.7%
$13.62M
$1.52M
'24 Q4
25-02-05
▲0.8%
$13.14M
−$4.07M
'25 Q1
25-05-14
▲1%
$15.01M
−$3.80M
'25 Q2
25-08-12
▲20.5%
$17.63M
−$2.31M
'25 Q3
25-11-12
▲18.1%
$16.08M
−$1.25M
'25 Q4
26-03-25
▲21.5%
$15.96M
−$2.23M
'26 Q1
26-05-13
LATEST
▲23.3%
$18.51M
−$312,000
'26 Q2
26-08-12
Earnings call
FY26 · Q2
2026-08-12
Second Quarter 2026 Financial Results Conference Call
Confident tone
MROSI commercial momentum
Payer access and formulary
Sales force expansion
Revenue
$18.51M
▲ 23.3% YoY Diluted EPS
$-0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2026-06-24
2026 Annual Meeting of Stockholders
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-13
Journey Medical Corp Q1 FY2026 Earnings Call
Confident tone
EMROSI launch momentum and growth
Payer reimbursement and GPO coverage
Refill-to-new prescription ratio and patient retention
Revenue
$15.96M
▲ 21.5% YoY Diluted EPS
$-0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-25
Journey Medical Corp Q4 FY2025 Earnings Call
Confident tone
Emrosi launch and commercial uptake
Profitability and adjusted EBITDA
Managed care and market access
Revenue
$16.08M*
▲ 18.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Journey Medical Corp Q3 FY2025 Earnings Call
Confident tone
Amrozi launch trajectory
Physician and patient feedback
Guidance and outlook
Revenue
$17.63M
▲ 20.5% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Journey Medical Corp Q2 FY2025 Earnings Call
Confident tone
EMROSI launch performance
Payer access and reimbursement
Accutane generic competition
Revenue
$15.01M
▲ 1% YoY Diluted EPS
$-0.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Journey Medical Corp Q1 FY2025 Earnings Call
Confident tone
Emrosi launch and product uptake
Clinical data and JAMA Dermatology publication
Dermatology sales force and commercial execution
Revenue
$13.14M
▲ 0.8% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-05
Journey Medical Corp Q4 FY2024 Earnings Call
Revenue
$13.62M*
▼ 10.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q2
2024-08-12
Journey Medical Corp Q2 FY2024 Earnings Call
Confident tone
DFD-29 launch readiness and PDUFA
Patent exclusivity runway
Core commercial brands performance
Revenue
$14.86M
▼ 13.5% YoY Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Journey Medical Corp Q1 FY2024 Earnings Call
Confident tone
DFD-29 rosacea launch opportunity
Profitability and cost optimization
Regulatory timeline and FDA review
Revenue
$13.03M
▲ 6.7% YoY Diluted EPS
$-0.53
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
Journey Medical Corp Q4 FY2023 Earnings Call
Revenue
$15.26M*
▼ 4.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Journey Medical Corp Q3 FY2023 Earnings Call
Revenue
$34.54M
▲ 114.3% YoY Diluted EPS
$0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Journey Medical Corp Q2 FY2023 Earnings Call
Revenue
$17.17M
▼ 6.1% YoY Diluted EPS
$-0.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-22
Journey Medical Corp Q1 FY2023 Earnings Call
Revenue
$12.21M
▼ 47.6% YoY Diluted EPS
$-0.57
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-29
Journey Medical Corp Q4 FY2022 Earnings Call
Revenue
$15.97M*
▼ 8.9% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Journey Medical Corp Q3 FY2022 Earnings Call
Revenue
$16.12M
▼ 17.8% YoY Diluted EPS
$-0.57
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Journey Medical Corp Q2 FY2022 Earnings Call
Revenue
$18.29M
▲ 19.6% YoY Diluted EPS
$-0.43
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Journey Medical Corp Q1 FY2022 Earnings Call
Revenue
$23.30M
▲ 117.3% YoY Diluted EPS
$-0.08
▼ 500% YoY
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-24
Journey Medical Corp Q4 FY2021 Earnings Call
Revenue
$17.52M*
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Showing 1–19 of 19 earnings calls
Key facts
CIK
1867066
CUSIP
48115J109
13F (30d)
71 filings
69 filers
Visit website
Investor relations